Concord Drugs Limited

BSE: CONCORD538965ISIN INE858L01010

Healthcare
Pharmaceuticals

BSE listing

Share price

₹75.30-1.72 (-2.23%)

as of 18 Sep 2026

52W high: ₹92.52
52W low: ₹61.00
Off 52W high: -18.61%
1M return: +5.18%
3M return: -2.37%
6M return: -1.91%
1Y return: +12.09%
20D avg volume: 5,299
50 DMA: ₹74.52
200 DMA: ₹78.04

Key ratios Consolidated

Market cap: ₹99.21 Cr
Current price: ₹75.30
52W high / low: ₹92.52 / ₹61.00
Face value: ₹10.00
P/E: 48.37
P/B: —
EPS (TTM): ₹1.56
Book value / share: —
ROE: —
ROCE: 5.90%
Operating margin: —
Net margin: —
Debt / equity: 0.28
Net debt: ₹13.32 Cr
Interest cover: 1.86
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 198.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	20.94	37.89	16.97	10.28	13.61	10.39	—
	0.01	0.01	0.02	0.00	0.00	0.00	—
	19.40	37.15	16.69	10.01	13.45	10.34	—
	16.52	35.07	14.38	7.76	10.81	8.65	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.26	1.75	1.24	1.09	0.89	1.24	—
	0.40	0.40	0.34	0.49	0.49	0.61	—
	0.35	0.35	0.31	0.34	0.37	0.38	—
	0.49	0.53	0.42	0.37	0.29	0.21	—
	1.54	0.75	0.30	0.27	0.16	0.06	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.54	0.75	0.30	0.27	0.16	0.06	—
	0.43	0.22	0.08	0.08	0.04	0.02	—
	1.11	0.53	0.22	0.19	0.12	0.04	—
	0.85	0.47	0.16	0.31	0.12	0.04	—
Key metrics
	2.29	1.50	0.95	1.10	1.02	1.05	—
	10.90%	4.00%	5.60%	10.70%	7.50%	10.10%	—
	5.30%	1.40%	1.30%	1.80%	0.90%	0.40%	—
	—	2.10%	—	2.00%	—	1.70%	—
	53.90%	264.70%	—	—	—	—	—
	825.00%	1,225.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	86.08	78.74	45.24	—
	0.04	0.03	0.01	—
	83.25	77.30	44.57	—
	73.73	68.03	35.81	—
	0.00	0.00	0.00	—
	5.34	4.97	4.63	—
	1.63	1.71	2.03	—
	1.35	1.37	1.43	—
	1.81	1.60	1.25	—
	2.86	1.47	0.69	—
	0.00	0.00	0.00	—
	2.86	1.47	0.69	—
	0.81	0.42	0.36	—
	2.05	1.05	0.34	—
	1.79	0.95	0.34	—
Key metrics
	5.84	4.55	4.15	—
	6.78%	5.80%	9.20%	—
	2.38%	1.30%	0.80%	—
	—	5.90%	7.00%	—
	—	74.00%	—	—
	—	208.80%	—	—
	—	-7.94	1.39	—
	—	-6.45	10.94	—
	—	0.28	0.50	—
	—	13.32	17.07	—
	—	198.5	252.1	—
Balance sheet
	—	74.89	65.14	—
	—	53.31	40.76	—
	—	0.28	0.12	—
	—	24.38	13.60	—
	—	25.52	25.27	—
	—	2.63	1.54	—
	—	10.94	11.57	—
	—	7.07	7.62	—
	—	21.07	26.18	—
	—	13.60	17.19	—
	—	11.79	15.87	—
	—	1.81	1.32	—
	—	48.51	34.11	—
Cash flow
	—	-6.77	3.72	—
	—	-1.13	-2.32	—
	—	8.06	-1.43	—
	—	1.17	2.33	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	20.89	35.55	16.84	10.07	13.38	0.79	—
	0.01	0.01	0.02	0.00	0.00	0.00	—
	19.35	34.83	16.57	9.81	13.23	7.95	—
	16.53	31.81	14.33	7.67	10.69	6.04	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.25	1.73	1.22	1.08	0.87	1.53	—
	0.35	0.34	0.30	0.40	0.42	0.53	—
	0.35	0.35	0.30	0.34	0.37	0.37	—
	0.49	0.53	0.41	0.37	0.28	0.21	—
	1.54	0.73	0.29	0.27	0.15	-7.15	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.54	0.73	0.29	0.27	0.15	-7.15	—
	0.43	0.22	0.08	0.08	0.04	0.01	—
	1.11	0.52	0.22	0.19	0.11	-7.16	—
	0.84	0.46	0.16	0.21	0.11	0.08	—
Key metrics
	2.24	1.42	0.89	1.01	0.94	-6.25	—
	10.70%	4.00%	5.30%	10.00%	7.00%	-791.10%	—
	5.30%	1.50%	1.30%	1.90%	0.80%	-906.30%	—
	—	2.00%	—	1.70%	—	-17.00%	—
	56.10%	4,400.00%	—	—	—	—	—
	909.10%	107.30%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	83.35	75.85	36.93	—
	0.04	0.03	0.01	—
	80.56	74.43	36.31	—
	70.34	64.50	28.22	—
	0.00	0.00	0.00	—
	5.28	4.90	4.39	—
	1.39	1.46	1.72	—
	1.34	1.36	1.42	—
	1.80	1.58	1.13	—
	2.83	1.45	0.64	—
	0.00	0.00	0.00	—
	2.83	1.45	0.64	—
	0.81	0.41	0.35	—
	2.04	1.04	0.30	—
	1.67	0.93	0.30	—
Key metrics
	5.56	4.27	3.78	—
	6.67%	5.60%	10.20%	—
	2.45%	1.40%	0.80%	—
	—	5.40%	6.10%	—
	—	105.40%	—	—
	—	246.70%	—	—
	—	-8.54	0.83	—
	—	-7.09	10.53	—
	—	0.24	0.44	—
	—	11.34	14.74	—
	—	194.7	280.6	—
Balance sheet
	—	71.85	58.58	—
	—	49.47	33.42	—
	—	0.27	0.12	—
	—	28.13	12.67	—
	—	18.35	19.13	—
	—	2.21	1.28	—
	—	10.91	11.54	—
	—	6.02	3.41	—
	—	18.02	19.62	—
	—	11.61	14.86	—
	—	9.80	13.55	—
	—	1.81	1.31	—
	—	48.51	34.11	—
Cash flow
	—	-7.37	3.16	—
	—	-1.13	-2.32	—
	—	8.65	-0.87	—
	—	1.17	2.33	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 45.08%

Holder	Type	Holding	Previous	Change
NAGI REDDY SEELAM	Promoter	23.23%	—	—
MANOJKUMARREDDY SEELAM	Promoter	13.50%	—	—
C SUSHMITHA	Public	8.35%	—	—
SEELAM KONI REDDY	Promoter	8.35%	—	—
PRANALI BANGAD	Public	2.28%	—	—
ANURADHA BANGAD	Public	2.28%	—	—
ANJANA BANGAD	Public	2.28%	—	—
VIKAS BANGAD	Public	2.28%	—	—
KOMAL SHARMA	Public	1.57%	—	—
GANGA DEVI LOYA	Public	1.48%	—	—
MOHAN THODUPUNURI	Public	1.15%	—	—
RAJENDER KUMAR AGARWAL	Public	1.13%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Copies of News paper publications of the Notice of the 31st AGM to be held on 30.09.20269 Sep 2026 · Company Update / Newspaper Publication
Letter to members as per regulation 36(1)(b)7 Sep 2026 · Company Update / General
Record date for Annual general meeting7 Sep 2026 · Corp. Action / Record Date
Book Closure for AGM to be held on 30.09.20267 Sep 2026 · Corp. Action / Book Closure
31st Annual Report of the Company7 Sep 2026 · Others / Reg. 34 (1) Annual Report
AGM to be held on 30.09.2026 at 09:00 AM7 Sep 2026 · AGM/EGM / AGM
Company has approved the notice and proposed to hold 31st AGM on 30.09.20267 Sep 2026 · Others / Outcome without intimation
Copy of News-paper publications for quarterly results ended 30th June 2026.12 Aug 2026 · Company Update / Newspaper Publication
Board of Directors have approved stand alone and consolidated Un-audited financial results for 30th June 202610 Aug 2026 · Result / Financial Results
Outcome of Board meeting10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Quarterly Results3 Aug 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (DP) Regulations13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Copy of Newspaper publication for audited results for year ended 31st March,2026.1 Jun 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance report under Regulation 24(A)29 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Financial Results for Year ending 31st March, 202629 May 2026 · Result / Financial Results
Company has approved financial results for Quarter and year ending 31st March,202627 May 2026 · Board Meeting / Outcome of Board Meeting
Company in its Board Meeting has approved financial results for period ended 31st March,202627 May 2026 · Result / Financial Results
Company in its Board Meeting has approved financial results for period ended 31st March,202627 May 2026 · Result / Financial Results
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve Financial Results for year ending 31.03.202618 May 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....6 May 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Certificate under Reg 74(5)10 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''> <tr> <td>Sr. No.</td> <td>Particulars</td> ....10 Apr 2026 · Others / Format of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....10 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Closure for the purpose of consideration of Audited (standalone and Consolidated) Results for the quarter and Financial year ending 31st March, 2026.27 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
News Paper publication of Q3 results17 Feb 2026 · Company Update / Newspaper Publication
General Update16 Feb 2026 · Company Update / General
Un-Audited Stand alone and Consolidated Results for Quarter Ended 31st Dec,2025.14 Feb 2026 · Result / Financial Results
Board of Directors approved financial results for 31 st December,202514 Feb 2026 · Board Meeting / Outcome of Board Meeting
Reconstitution of Committees14 Feb 2026 · Company Update / General
Announcement under Regulation 30 of LODR14 Feb 2026 · Company Update / Retirement
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited financials Results ....2 Feb 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of SEBI (DP) regulations20 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Company has received purchase orders from various entities for supply of it''s products.30 Dec 2025 · Company Update / Award of Order / Receipt of Order
Closure of Trading Window29 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Koni Reddy25 Nov 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Nagi Reddy25 Nov 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Manoj Kumar Reddy25 Nov 2025 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosure under SEBI (PIT) Regulations24 Nov 2025 · Company Update / Code of Conduct under SEBI (PIT) Regulations, 2015
New Paper publication of financial results for Quarter and Half year ended 30 Sep,2025.22 Nov 2025 · Company Update / Newspaper Publication

Board meetings

10 Aug 2026 Board Meeting - Financial Results